neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call
July 16, 2020 15:14 ET | NeuroMetrix, Inc.
WOBURN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on...
neurometrix_rgb.jpg
NeuroMetrix Reports DPNCheck® Expansion in China
July 09, 2020 13:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test...
neurometrix_rgb.jpg
NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
June 25, 2020 13:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral...
Quell Wearable Pain Relief for Chronic Knee Pain
NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device
June 10, 2020 13:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes...
neurometrix_rgb.jpg
NeuroMetrix Reports Q1 2020 Financial Results
April 23, 2020 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020.  The Company is a leading...
neurometrix_rgb.jpg
NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia
April 16, 2020 13:30 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH-funded, randomized, pragmatic...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for First Quarter 2020 Financial Results Conference Call
April 16, 2020 11:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on...
neurometrix_rgb.jpg
NeuroMetrix Announces 2020 Annual Meeting of Shareholders Will Be Held in Virtual Meeting Format Only
April 10, 2020 13:42 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that, due to the public health impact of the COVID-19 pandemic and in accordance with orders issued...
neurometrix_rgb.jpg
NeuroMetrix Provides Quell® Technology Commercial Strategy and Pipeline Update
March 11, 2020 11:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell technology commercial strategy and pipeline. An estimated 100 million US...
neurometrix_rgb.jpg
NeuroMetrix Reports Clinical Studies Recently Published on DPNCheck®
March 05, 2020 12:14 ET | NeuroMetrix, Inc.
WOBURN, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a point-of-care...